Lenvima (lenvatinib)

About Merck

Merck & Co., Inc. is a leading research-intensive biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey. With a market valuation of approximately $282 billion, the company has built a legacy of breakthrough medicines and vaccines, including the blockbuster cancer immunotherapy Keytruda and vaccines like Gardasil. Merck operates globally, reaching 92% of the world's countries with its products and serving over 450 million people with medicines and vaccines in 2024.

About Eisai

Eisai is a Japanese pharmaceutical giant with a strong commitment to human health care (hhc), focusing on addressing unmet medical needs in neurology, oncology, and neglected tropical diseases. The company has achieved significant breakthroughs in Alzheimer's treatment with Lecanemab and maintains a robust oncology portfolio including multi-targeted kinase inhibitors. Eisai is also deeply committed to global health initiatives, providing treatments for neglected tropical diseases in developing countries while maintaining strong financial performance as a publicly traded company.

Therapeutic Areas